Using transcriptome and chromatin immunoprecipitation profiling of PDA cells treated with the MEK inhibitor, Trametinib (MEKi), researchers identified transcriptional antagonism between c-MYC and the master transcription factors for lysosome gene expression, the MiT/TFE proteins.
[Cancer Discovery]